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18 years, admitted via the emergency department, and their blood, sputum, or urine culture
revealed the growth of Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis. From
each patient only the first isolate from the infection site was included. Antimicrobial suscep-
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Antimicrobial susceptibility of Enterobacteriaceae 585Results: Overall, 827 patients were included, with 354 (42.8%) coming from the community and
473 (57.2%) referred from a nursing home. Of the isolates acquired in nursing home, 45.5%
(215/473) harbored ESBL. By contrast, 20.6% (73) of 354 isolates acquired in the community
exhibited the ESBL production phenotype (p < 0.001). Of the isolates obtained from blood, ur-
ine, or sputum, 28.2% (37/131), 36.0% (208/578), or 36.4% (43/118) harbored ESBL, respec-
tively, whereas 41% (211) of 515 E. coli isolates, 34.3% (72) of 210 K. pneumoniae, and 4.9%
(5) of 102 P. mirabilis had ESBL. In general, the isolates from a nursing home or those with ESBL
had lower antimicrobial susceptibility rates than those from the community or those without
ESBL production. Only amikacin, piperacillin/tazobactam, ertapenem, and imipenem/merope-
nem were active against >90% Enterobacteriaceae isolates, irrespective of ESBL production.
Conclusion: ESBL production was common among clinical Enterobacteriaceae isolates, espe-
cially E. coli or those isolated from nursing home residents.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Extended-spectrum beta-lactamases (ESBLs) are the en-
zymes produced by certain bacteria, especially among
Enterobacteriaceae such as Escherichia coli, Klebsiella
pneumoniae, and Proteus mirabilis, and are able to hy-
drolyze extended-spectrum cephalosporins, such as cefta-
zidime, ceftriaxone, cefotaxime, and oxyimino-
monobactams.1 The prevalence rate of ESBL-producing
Enterobacteriaceae has been increasing in recent years.
In a review article, it is estimated that 5e8% of E. coli
isolates from Korea, Japan, Malaysia, and Singapore had
ESBL, while the figure was 12e24% in Taiwan, Thailand, the
Philippines, and Indonesia.1 In the Asia-Pacific region, an
antimicrobial surveillance study, the Study for Monitoring
Antimicrobial Resistance Trends (SMART), in 2008, collected
2370 unique aerobic and facultative gram-negative bacilli
associated with intra-abdominal infections (IAIs) from 11
countries. High rates of ESBL-producing E. coli and K.
pneumoniae were observed in China (59.1% and 34.4%,
respectively), India (61.2% and 46.8%, respectively), and
Thailand (53.0% and 23.1%, respectively), particularly those
causing hospital-associated intra-abdominal infections.2 It
also revealed the ESBL prevalence increased from 13% in
2002 to 28% in 2006 among Enterobacteriaceae.3 Likewise,
in a 7-year study at a tertiary hospital in Taiwan, a signifi-
cant increase was evident for ESBL production among E.
coli (from 4.8% to 10.0%) and K. pneumoniae (from 15.0% to
23.4%) isolates.4
Though ESBL-producing E. coli and K. pneumoniae were
increasing, inappropriate antibiotic therapy was often
noted and was associated with high mortality and prolonged
hospitalization. In our previous study of 111 adults with
bacteremic pneumonia caused by ESBL-producing E. coli
and K. pneumoniae, 54.1% patients received inappropriate
empiric antimicrobial therapy which was linked to a poor
prognosis.5 Moreover, inappropriate empirical antibiotics
therapy has been often prescribed in cases of ESBL-
producing E. coli, K. pneumoniae, or P. mirabilis bacter-
emia in the emergency department and was associated with
longer hospital stay.6 Selection of appropriate antimicro-
bials against E. coli, K. pneumoniae, and P. mirabilis,especially those with ESBL-production, therefore, was of
clinical significance.
In this study we aim to study the antimicrobial suscep-
tibility of clinical E. coli, K. pneumoniae, or P. mirabilis
isolates in hospitalized patients with community-onset in-
fections, in order to guide clinicians to select appropriate
empirical antibiotics.Methods
A retrospective study was performed at the Department of
Health and Welfare, Tainan Hospital, a district hospital at
southern Taiwan. Patients admitted between July 2009 and
June 2011 were included if they were older than 18 years,
admission via the emergent department, and blood,
sputum, or urine culture that revealed one of either E. coli,
K. pneumoniae, and P. mirabilis. Clinical data, including
age, sex, and sample category, were retrieved from the
electronic database. The information of the patient’s
source was mandatorily queried and recorded for all visitors
in the emergency department.
Microbiology analysis
Urine and sputum samples were transported to the labo-
ratory and refrigerated at 4C, and processed within 12
hours according to the following procedures. A calibrated
loop was used and seeded in a 1-mL aliquot to 90-mm petri
dishes containing CHROMagar (Becton Dickinson, Franklin
Lakes, NJ, USA). Isolates were identified by the morphology
and color in the chromogenic agar, followed by the confir-
mation of species identification by BD GNB ID or BD E/NF
crystal kit (Becton Dickinson). Blood cultures were pro-
cessed in the BD BACTEC 9240 system (Becton Dickinson).
Antibiotic susceptibility was determined using the disk
diffusion method in accordance with the procedures of the
Clinical and Laboratory Standards Institute (CLSI), inter-
preted as being susceptible according to the susceptible
zone criteria of CLSI issued in 2011 (M100-S21).7 The drugs
tested included ampicillin, ampicillin/sulbactam, genta-
micin, amikacin, cefazolin, cefuroxime, ceftriaxone,
1791 patients
Exclude 295 (16.5%) admissions 
without bacterial cultures
1496 patients with blood, urine, or sputum cultures
473 from nursing home354 from the community
215 (45.5%) harbored ESBL73 (20.6%) harbored ESBL
p < 0.001
827 patients with cultures yielding Escherichia coli,
Klebsiella pneumoniae, or Proteus mirabilis
Figure 1. Community-acquired and nursing home-acquired
extended spectrum beta-lactamase-producing Enter-
obacteriaceae isolates included in the present study.
ESBL Z extended spectrum beta-lactamase.
586 H.-C. Liu et al.ceftazidime, cefepime, ciprofloxacin, ertapenem, imipe-
nem, or meropenem. A difference of 5 mm between the
zone diameters of either of cephalosporin disks and their
respective cephalosporin/clavulanate disks was taken to be
phenotypic confirmation of ESBL production.Table 1 Clinical characters of 827 hospitalized adults infect
mirabilis.
Characters
Total, n Z 827 Comm
Sex, male 337 (40.7) 120 (33
Clinical specimen
Urine 578 (69.9) 235 (66
Sputum 118 (14.3) 47 (13
Blood 131 (15.8) 72 (20
Bacterial species
E. coli 515 (62.3) 227 (64
K. pneumoniae 210 (25.4) 90 (25
P. mirabilis 102 (12.3) 37 (10
Susceptibility rate
Ampicillin/sulbactam 319 (38.6) 194 (54
Piperacillin 320 (38.7) 184 (52
Piperacillin/tazobactam 809 (97.8) 348 (98
Cefazolin 253 (30.6) 161 (45
Cefuroxime 397 (48.1) 237 (66
Cefotaxime 497 (60.1) 265 (74
Ceftazidime 499 (60.3) 264 (74
Cefepime 534 (64.6) 280 (79
Gentamicin 401 (48.5) 233 (65
Amikacin 781 (94.4) 348 (98
Ciprofloxacin 371 (44.9) 218 (61
Ertapenem 814 (98.4) 350 (98
Imipenem or meropenem 827 (100) 354 (10
ESBL production 288 (34.8) 73 (20
ESBL Z extended spectrum beta-lactamase.Data analysis
Only one clinical isolate was included from each admission.
From each patient only the first isolate from the infection
site was included. If there was a blood isolate in addition to
concurrent urine or sputum isolates, only the blood isolate
was taken into account. If urine and sputum yielded the
growth of different species, only one was included, ac-
cording to the clinical diagnosis at admission.
Statistical analysis
Statistical analysis was performed by the statistical soft-
ware (SPSS, version 13.0; SPSS Inc., Chicago, IL, USA).
Descriptive statistics, including the means, standard de-
viations, and ranges, were used to analyze the continuous
variables. For categorical variables, the percentages and
confidence intervals were used. Independent t test was
used for the continuous variables and a Chi-square test or
Fisher’s exact test for the categorical variables. A two-
tailed p value < 0.05 was considered to be statistically
significant.Results
During the study period, there were 1791 patients admitted
to the study hospital, of which 295 (16.5%) had no patho-
gens isolated from blood, urine, or sputum (Figure 1). E.ed by Escherichia coli, Klebsiella pneumoniae, or Proteus
Case number (%) p
unity, n Z 354 Nursing home, n Z 473
.9) 217 (45.9) 0.001
0.009
.4) 343 (72.5)
.3) 71 (15.0)
.3) 59 (12.5)
0.35
.1) 288 (60.9)
.4) 120 (25.4)
.5) 65 (13.7)
.8) 125 (26.4) <0.001
.0) 136 (28.8) <0.001
.3) 461 (97.5) 0.41
.5) 92 (19.5) <0.001
.9) 160 (33.8) <0.001
.9) 232 (49.0) <0.001
.6) 235 (49.7) <0.001
.1) 254 (53.7) <0.001
.8) 168 (35.5) <0.001
.3) 433 (91.5) <0.001
.6) 153 (32.3) <0.001
.9) 464 (98.1) 0.38
0.0) 473 (100.0) 1.00
.6) 215 (45.5) <0.001
Antimicrobial susceptibility of Enterobacteriaceae 587coli, K. pneumoniae, or P. mirabilis was isolated from a
total of 827 (55.3%) patents, which were included in the
present study. Of 473 Enterobacteriaceae isolates from
nursing homes, 215 (45.5%) exhibited the ESBL production
phenotype, and in contrast only 73 (20.6%) of 354 isolates
acquired in the community did (p < 0.001). Patient age of
those from nursing homes was similar to those from the
community (75.3 years vs. 73.9 years, p Z 0.23; Table 1).
Nevertheless female predominance was more evident in
those from the community than nursing home residents
(66.1% vs. 54.1%, p Z 0.001).
Clinical isolates in the present study were obtained from
urine (578 isolates, 69.9%), blood (131, 15.8%), and sputum
(118, 14.3%), as shown in Table 2. Of urine and blood iso-
lates, E. coli predominated, accounting for 66.6% andTable 2 Ciprofloxacin susceptibility and extended spectrum bet
or blood isolates.
Microbiological characteristics Community,
Urine isolates, n Z 578
Escherichia coli, n Z 385 (66.6%) 163
Ciprofloxacin-nonsusceptibility 80 (49.1)
ESBL production 41 (25.2)
Botha 40 (24.5)
Klebsiella pneumoniae, n Z 114 (19.7%) 41
Ciprofloxacin-nonsusceptibility 18 (43.9)
ESBL production 11 (26.8)
Botha 10 (24.4)
Proteus mirabilis, n Z 79 (13.7%) 31
Ciprofloxacin-nonsusceptibility 5 (16.1)
ESBL production 2 (6.5)
Botha 1 (3.2)
Sputum isolates, n Z 118
Escherichia coli, n Z 37 (31.3%) 14
Ciprofloxacin-nonsusceptibility 11 (78.6)
ESBL production 6 (42.9)
Botha 6 (42.9)
Klebsiella pneumoniae, n Z 65 (55.1%) 30
Ciprofloxacin-nonsusceptibility 6 (20.0)
ESBL production 5 (16.7)
Botha 4 (13.3)
Proteus mirabilis, n Z 16 (13.6%) 3
Ciprofloxacin-nonsusceptibility 0 0
ESBL production 0
Botha 0
Blood isolates, n Z 131
Escherichia coli, n Z 93 (71.0%) 50
Ciprofloxacin-nonsusceptibility 11 (22.0)
ESBL production 5 (10.0)
Botha 3 (6.0)
Klebsiella pneumoniae, n Z 31 (23.7%) 19
Ciprofloxacin-nonsusceptibility 4 (21.1)
ESBL production 3 (15.8)
Botha 3 (15.8)
Proteus mirabilis, n Z 7 (0.2%) 3
Ciprofloxacin-nonsusceptibility 1 (33.3)
ESBL production 0
Botha 0
a Co-existing ESBL production and ciprofloxacin-nonsusceptibility ph
ESBL Z extended-spectrum beta-lactamase.71.0%, respectively. However, K. pneumoniae (55.1%) was
the major pathogen of sputum isolates.
Of clinical specimens with Enterobacteriaceae, more
urine specimens (72.5% vs. 66.4%) but less blood samples
(12.5% vs. 20.3%) were noted in nursing home residents than
those in the community. Species distribution of the isolates
from nursing home or the community was similar, with the
predominance of E. coli. Nevertheless, susceptibility rates
of bacterial isolates of the same species from nursing home
to all drugs but piperacillin/tazobactam, ertapenem, or
imipenem were significantly lower than those from the
community (Table 1).
Among E. coli isolates acquired in the community, cip-
rofloxacin nonsusceptibility rates varied among those from
different specimens, ranging from 22.0% in 93 blooda-lactamase production in different species of urine, sputum,
n Z 354 Nursing home, n Z 473 p
222
169 (76.1) <0.001
117 (52.7) <0.001
111 (50.0) <0.001
73
21 (65.8) 0.02
34 (46.6) 0.04
32 (43.8) 0.04
48
14 (29.2) 0.19
3 (6.2) 0.97
3 (6.2) 0.55
23
19 (82.6) 0.76
16 (69.6) 0.11
14 (60.9) 0.29
35
25 (71.4) <0.001
16 (45.7) 0.01
15 (42.9) 0.01
13
3 (23.1) 0.36
0
0
43
34 (79.1) <0.001
26 (60.5) <0.001
26 (60.5) <0.001
12
7 (58.3) 0.04
3 (25.0) 0.53
2 (16.7) 0.95
4
1 (25.0) 0.81
0
0
enotype.
Table 3 Characters of hospitalized adults infected by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates
with or without extended spectrum beta-lactamase production.
Characteristics ESBL, n Z 288 No ESBL, n Z 539 p
Age (y) 75.7  13.4 74.2  15.9 0.16
Sex, male 149 (51.7) 188 (34.9) <0.001
Clinical specimen 0.23
Urine 208 (72.2) 370 (68.6)
Sputum 43 (14.9) 75 (13.9)
Blood 37 (12.8) 94 (17.4)
Bacterial species <0.001
E. coli 211 (73.3) 304 (56.4)
K. pneumoniae 72 (25.0) 138 (25.6)
P. mirabilis 5 (1.7) 97 (18.0)
Antimicrobial susceptibility
Amikacin 262 (91.0) 519 (96.3) 0.001
Gentamicin 48 (16.7) 353 (65.5) <0.001
Ampicillin/sulbactam 4 (1.4) 315 (58.4) <0.001
Piperacillin/tazobactam 271 (94.1) 538 (99.8) <0.001
Ertapenem 280 (97.2) 534 (99.1) 0.04
Imipenem or meropenem 211 (100.0) 72 (100.0) 1.00
Ciprofloxacin 18 (6.2) 353 (65.5) <0.01
Data are presented as n (%) or mean  standard deviation.
ESBL Z extended spectrum beta-lactamase.
588 H.-C. Liu et al.isolates, 49.1% in 385 urine isolates, to 78.6% in 37 sputum
isolates (Table 2). By contrast, ciprofloxacin non-
susceptibility rates of community-acquired K. pneumoniae
isolates ranged from 20.0% in 65 sputum isolates, 21.1% in
31 blood isolates, to 43.9% in 114 urine isolates. Of 37
community-acquired P. mirabilis isolates, mainly urine
isolates, 16.2% (31) were not susceptible to ciprofloxacin.
In total, 288 (34.8%) isolates exhibited ESBL production
phenotype. By species, 41.0% (211) of 515 E. coli isolates,
34.3% (72) of 210 K. pneumoniae, and 4.9% (5) of 102 P.
mirabilis were ESBL producers. By clinical specimen, 36.0%
(208) of 578 urine isolates, 36.4% (43) of 118 sputum iso-
lates, and 28.2% (37) of 131 blood isolates were ESBL pro-
ducers. The isolates from nursing homes were more likely
to have ESBL production (45.5%, 215/473 vs. 20.6%, 73/354;Figure 2. Antimicrobial susceptibility of Escherichia coli or
Klebsiella pneumoniae isolates with and without extended
spectrum beta-lactamase to seven drugs. ESBL Z extended
spectrum beta-lactamasep < 0.001; Table 1) or coexisting ESBL production and cip-
rofloxacin nonsusceptibility phenotype (42.9%, 203/473 vs.
18.9%, 67/354; p < 0.001) than those from the community.
Such a difference was evident for E. coli and K. pneumoniae
isolates, but not P. mirabilis (Table 2).
As compared with non-ESBL producers, ESBL producers
usually had lower antimicrobial susceptibility rates, as
shown in Table 3. Of note, only 1.4%, 6.2%, and 16.7% of
ESBL producers were susceptible to ampicillin/sulbactam,
ciprofloxacin, and gentamicin, respectively. Amikacin,
piperacillin/tazobactam, ertapenem, and imipenem or
meropenem were in vitro active against >90% of Enter-
obacteriaceae isolate, irrespective of ESBL production
(Table 3). However, amikacin and piperacillin/tazobactam
were in vitro active against 69.4% and 84.7%, respectively,
of ESBL-producing K. pneumoniae isolates (Figure 2).Discussion
The ESBL-production rate among E. coli, K. pneumoniae,
and P. mirabilis isolates in our study was 20.6%, which was
compatible to the ESBL prevalence rate of 12e24% among
E. coli isolates in Taiwan and other Southeast Asia area.1
In the SMART study, 2009e2010, ESBL-producing patho-
gens comprised 28.2% of all Enterobacteriaceae isolates.8
Of note, one fifth of the isolates presumably acquired in
the community had ESBL and such a finding warrants more
detailed clinical studies. The substantial prevalence rate
of ESBL production among Enterobacteriaceae isolates
warrants clinical and public health attention.
Residence in a nursing home, as well as living in the
hospitals, was associated with a higher risk for acquiring
ESBL-producing Enterobacteriaceae isolates. Nursing home
Antimicrobial susceptibility of Enterobacteriaceae 589residents often had nasogastric tube or urinary catheter
placement and antimicrobial exposure. Among 393 patients
with community-onset urinary tract infections due to
Enterobacteriaceae, nasogastric tube placement and
recent hospitalization were independently associated with
the acquisition of ESBL-producing pathogens.9 Similarly risk
factors associated with ESBL production among community-
onset E. coli bacteremia included recent antibiotic expo-
sure and urinary catheter placement.10 More specifically,
previous exposure to oxyimino-cephalosporins was an in-
dependent predictor for ESBL-producer infection among E.
coli bacteremia.11
The prevalence of ESBL phenotype varies not only among
species, but also among the isolates from different body
sites. Among clinical Enterobacteriaceae isolates in
Taiwanese intensive care units in 2008, the prevalence of
ESBL-producing isolates was 26% in K. pneumoniae, 16%
Serratia marcescens, 14% E. coli, and 13% P. mirabilis iso-
lates.12 By contrast, these figures in our study were higher,
34% in K. pneumoniae and 41% E. coli isolates, suggestive of
substantial antimicrobial resistance in the community. The
majority of Enterobacteriaceae isolates with ESBL were E.
coli isolates in the present study, in accordance with the
results of the SMART study that of nearly 700 Enter-
obacteriaceae isolates with ESBLs, AmpC b-lactamases, or
carbapenemases, E. coli predominated (63%),13 reflecting
its major role in human infection, frequent confronting of
antimicrobial selective pressure, or both.
Most of our ESBL-producing Enterobacteriaceae isolates
were nonsusceptible to ciprofloxacin, 93.8%, a figure higher
than that in Enterobacteriaceae isolates without ESBL,
34.5%. Such a finding was in agreement with published
data.14,15 Coexisting fluoroquinolones resistance in our
ESBL-producers may be related to previous frequent expo-
sure to antimicrobial agents in nursing home residents.
Although carbapenem resistance has been increasingly
recognized in Taiwan,16,17 there were few carbapenem-
resistant Enterobacteriaceae isolates in this study. The
carbapenem class remains a suitable choice for infectious
diseases due to ESBL-producing Enterobacteriaceae. Be-
sides, two drugs, amikacin and piperacillin/tazobactam,
can be potential alternatives, if patients were allergic or
intolerant to the carbapenems. Since there were significant
differences in antibiotic susceptibility between clinical
isolates from the community and nursing home, the clini-
cians in the emergency room setting should pay attention to
the patients from nursing homes in empirical prescription of
antimicrobial therapy. The antibiotics with a low suscepti-
bility rate (<80%), including ciprofloxacin, may be avoided
as initial therapy for nursing home residents with severe
infections.
There were some limitations in our study. Firstly, it is a
descriptive analysis of susceptibility data of clinical isolates
and no clinical details, such as prior antimicrobial exposure
or hospitalization, underlying disease, or clinical signifi-
cance of each isolate, were available. However, our results
could reflect resistance burden in community-onset in-
fections due to Enterobacteriaceae. Secondly, only three
species with confirmatory ESBL tests recommended by the
CLSI were included for the study. Such results certainly
underestimated the extent of ESBL production among all
Enterobacteriaceae isolates. Thirdly, the CLSI susceptibilitycriteria changed years, so the susceptibility data may not
be applicable or comparable to susceptible data form other
geographic regions or study periods. Nevertheless, these
regional susceptibility data of ESBL-producing E. coli, K.
pneumoniae, and P. mirabilis isolates can guide the
appropriate choice of empirical antibiotics.
In conclusion, ESBL production is not uncommon among
frequently encountered community-onset Enter-
obacteriaceae isolates, especially E. coli and those isolated
from nursing home residents. Concurrent ciprofloxacin
resistance was common among ESBL-producers. To opti-
mize the appropriateness of empirical antimicrobial ther-
apy, continuing resistance surveillance in different clinical
settings or hospitals is warranted.Conflicts of interest
All authors declare no conflicts of interest.References
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